我国乳腺癌预防若干问题的思考_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

瞿亚军 ¹ ,  吕青 ²

1. ;
2. ;

Corresponding author：

吕青, Email: lqlq1963@163.com

Keywords：

DOI：

10.7507/1007-9424.202009088

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 瞿亚军, 吕青. 我国乳腺癌预防若干问题的思考. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(11): 1334-1339. doi: 10.7507/1007-9424.202009088 Copy

1.	李贺, 郑荣寿, 张思维, 等. 2014年中国女性乳腺癌发病与死亡分析. 中华肿瘤杂志, 2018, 40(3): 166-171.
2.	Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
3.	陈万青, 郑荣寿. 中国女性乳腺癌发病死亡和生存状况. 中国肿瘤临床, 2015, 42(13): 668-674.
4.	国家统计局. 中华人民共和国2018年国民经济和社会发展统计公报. 2019. http://www.stats.gov.cn/tjsj/zxfb/201902/t20190228_1651265.html.
5.	世界人口网. http://www.renkou.org.cn/.
6.	Song QK, Wang XL, Zhou XN, et al. Breast cancer challenges and screening in China: lessons from current registry data and population screening studies. Oncologist, 2015, 20(7): 773-779.
7.	DeSantis CE, Fedewa SA, Goding Sauer A, et al. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin, 2016, 66(1): 31-42.
8.	黄育北, 佟仲生, 陈可欣, 等. 《中国女性乳腺癌筛查指南》解读(精简版). 中国肿瘤临床, 2019, 46(9): 433-441.
9.	Huang Y, Dai H, Song F, et al. Preliminary effectiveness of breast cancer screening among 1. 22 million Chinese females and different cancer patterns between urban and rural women. Sci Rep, 2016, 6: 39459.
10.	陈万青, 李霓, 石菊芳, 等. 中国城市癌症早诊早治项目进展. 中国肿瘤, 2019, 28(1): 23-25.
11.	妇幼健康司. 中国妇幼健康事业发展报告(2019). 国家卫生健康委员会官网, 2019 年5 月. http://www.nhc.gov.cn/fys/s7901/201905/bbd8e2134a7e47958c5c9ef032e1dfa2.shtml.
12.	Chen WQ, Zheng RS, Zhang SW, et al. Report of incidence and mortality in china cancer registries, 2008. Chin J Cancer Res, 2012, 24(3): 171-180.
13.	Chen WQ, Zheng RS, Zhang SW, et al. Report of cancer incidence and mortality in China, 2010. Ann Transl Med, 2014, 2(7): 61.
14.	Chen WQ, Zheng RS, Zuo TT, et al. National cancer incidence and mortality in China, 2012. Chin J Cancer Res, 2016, 28(1): 1-11.
15.	Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
16.	Wang BH, He MF, Wang LM, et al. Breast cancer screening among adult women in China, 2010. Prev Chronic Dis, 2013, 10: E183.
17.	包鹤龄, 王临虹, 王丽敏, 等. 中国 2013 年 35~69 岁女性人群子宫颈癌和乳腺癌筛查率及影响因素研究. 中华流行病学杂志, 2018, 39(2): 208-212.
18.	徐兵河. 乳腺癌的明天是什么?. 医脉通. 2018 年 8 月 21 日. http://news.medlive.cn/cancer/info-progress/show-147795_53.html.
19.	Breen N, Gentleman JF, Schiller JS. Update on mammography trends: comparisons of rates in 2000, 2005, and 2008. Cancer, 2011, 117(10): 2209-2218.
20.	杨非, 黄源, 应桂英, 等. 四川省基层医疗卫生服务机构开展宫颈癌和乳腺癌筛查能力的调查. 中国全科医学, 2014, 17(18): 2118-2122.
21.	Onega T, Beaber EF, Sprague BL, et al. Breast cancer screening in an era of personalized regimens: a conceptual model and National Cancer Institute initiative for risk-based and preference-based approaches at a population level. Cancer, 2014, 120(19): 2955-2964.
22.	冯雅靖, 方利文, 王卓群, 等. 在中国农村地区妇女人群中整合开展主要慢性病与“两癌”筛查的可行性分析. 中国慢性病预防与控制, 2016, 24(6): 466-469.
23.	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019 版). 中国癌症杂志, 2019, 29(8): 609-680.
24.	中国抗癌协会国家肿瘤临床医学研究中心(天津医科大学肿瘤医院). 中国女性乳腺癌筛查指南. 中国肿瘤临床, 2019, 46(9): 430-432.
25.	Zhang J, Sun J, Chen J, et al. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5 931 Chinese women with breast cancer. Breast Cancer Res Treat, 2016, 158(3): 455-462.
26.	Lang GT, Shi JX, Hu X, et al. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2 991 patients and 1, 043 controls by next-generation sequencing. Int J Cancer, 2017, 141(1): 129-142.
27.	Yao L, Sun J, Zhang J, et al. Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations. Breast Cancer Res Treat, 2016, 156(3): 441-445.
28.	Howell A, Anderson AS, Clarke RB, et al. Risk determination and prevention of breast cancer. Breast Cancer Res, 2014, 16(5): 446.
29.	Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst, 1999, 91(18): 1541-1548.
30.	Schonfeld SJ, Pee D, Greenlee RT, et al. Effect of changing breast cancer incidence rates on the calibration of the Gail model. J Clin Oncol, 2010, 28(14): 2411-241.
31.	NCCN. NCCN clinical practice guidlines: Breast cancer risk reducetion, version 1.2020. Fort Washington: NCCN, Inc, 2020.
32.	Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO Clinical practice guideline update. J Clin Oncol, 2019, 37(33): 3152-3165.
33.	宋丰举, 刘雪鸥, 黄育北, 等. 中国女性良性乳腺疾病的流行现状、危险因素及对乳腺癌筛查效果的影响研究. 成都: 全国肿瘤流行病学和肿瘤病因学学术会议论文集, 2015.
34.	Cheng J, Qiu S, Raju U, et al. Benign breast disease heterogeneity: association with histopathology, age, and ethnicity. Breast Cancer Res Treat, 2008, 111(2): 289-296.
35.	新浪网. 中国人口协会发布中国乳腺疾病调查报告. 2010 年 2 月 1 日. http://eladies.sina.com.cn/nx/2010/0201/1059966477.shtml.
36.	Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med, 2005, 353(3): 229-237.
37.	American Cancer Society. Breast cancer facts & figures 2019-2020. Atlanta: American Cancer Society, Inc. 2019.
38.	Pankratz VS, Degnim AC, Frank RD, et al. Model for individualized prediction of breast cancer risk after a benign breast biopsy. J Clin Oncol, 2015, 33(8): 923-929.
39.	Wang Y, Gao Y, Battsend M, et al. Development of a risk assessment tool for projecting individualized probabilities of developing breast cancer for Chinese women. Tumour Biol, 2014, 35(11): 10861-10869.
40.	Dorjgochoo T, Deming SL, Gao YT, et al. History of benign breast disease and risk of breast cancer among women in China: a case-control study. Cancer Causes Control, 2008, 19(8): 819-828.
41.	Jacobs TW, Byrne C, Colditz G, et al. Radial scars in benign breast-biopsy specimens and the risk of breast cancer. N Engl J Med, 1999, 340(6): 430-436.
42.	张安秦, 夏建红, 王颀, 等. 广东地区妇女乳腺癌高危因素分析与对策. 南方医科大学学报, 2009, 29(7): 1451-1453.
43.	Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 2013, 31(23): 2942-296.
44.	ACS. Breast cancer prevention and early detection. American Cancer Society, 2020. https://www.cancer.org/content/dam/CRC/PDF/Public/8579.00.pdf.
45.	American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Practice bulletin No. 164: Diagnosis and management of benign breast disorders. Obstet Gynecol, 2016, 127(6): e141-e156.
46.	Cuzick J, DeCensi A, Arun B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol, 2011, 12(5): 496-503.
47.	Lavoué V, Fritel X, Antoine M, et al. Clinical practice guidelines from the French College of Gynecologists and Obstetricians (CNGOF): benign breast tumors - short text. Eur J Obstet Gynecol Reprod Biol, 2016, 200: 16-23.
48.	Vogel VG. Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction. BMC Med, 2015, 13: 63.

1. 李贺, 郑荣寿, 张思维, 等. 2014年中国女性乳腺癌发病与死亡分析. 中华肿瘤杂志, 2018, 40(3): 166-171.
2. Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
3. 陈万青, 郑荣寿. 中国女性乳腺癌发病死亡和生存状况. 中国肿瘤临床, 2015, 42(13): 668-674.
4. 国家统计局. 中华人民共和国2018年国民经济和社会发展统计公报. 2019. http://www.stats.gov.cn/tjsj/zxfb/201902/t20190228_1651265.html.
5. 世界人口网. http://www.renkou.org.cn/.
6. Song QK, Wang XL, Zhou XN, et al. Breast cancer challenges and screening in China: lessons from current registry data and population screening studies. Oncologist, 2015, 20(7): 773-779.
7. DeSantis CE, Fedewa SA, Goding Sauer A, et al. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin, 2016, 66(1): 31-42.
8. 黄育北, 佟仲生, 陈可欣, 等. 《中国女性乳腺癌筛查指南》解读(精简版). 中国肿瘤临床, 2019, 46(9): 433-441.
9. Huang Y, Dai H, Song F, et al. Preliminary effectiveness of breast cancer screening among 1. 22 million Chinese females and different cancer patterns between urban and rural women. Sci Rep, 2016, 6: 39459.
10. 陈万青, 李霓, 石菊芳, 等. 中国城市癌症早诊早治项目进展. 中国肿瘤, 2019, 28(1): 23-25.
11. 妇幼健康司. 中国妇幼健康事业发展报告(2019). 国家卫生健康委员会官网, 2019 年5 月. http://www.nhc.gov.cn/fys/s7901/201905/bbd8e2134a7e47958c5c9ef032e1dfa2.shtml.
12. Chen WQ, Zheng RS, Zhang SW, et al. Report of incidence and mortality in china cancer registries, 2008. Chin J Cancer Res, 2012, 24(3): 171-180.
13. Chen WQ, Zheng RS, Zhang SW, et al. Report of cancer incidence and mortality in China, 2010. Ann Transl Med, 2014, 2(7): 61.
14. Chen WQ, Zheng RS, Zuo TT, et al. National cancer incidence and mortality in China, 2012. Chin J Cancer Res, 2016, 28(1): 1-11.
15. Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
16. Wang BH, He MF, Wang LM, et al. Breast cancer screening among adult women in China, 2010. Prev Chronic Dis, 2013, 10: E183.
17. 包鹤龄, 王临虹, 王丽敏, 等. 中国 2013 年 35~69 岁女性人群子宫颈癌和乳腺癌筛查率及影响因素研究. 中华流行病学杂志, 2018, 39(2): 208-212.
18. 徐兵河. 乳腺癌的明天是什么?. 医脉通. 2018 年 8 月 21 日. http://news.medlive.cn/cancer/info-progress/show-147795_53.html.
19. Breen N, Gentleman JF, Schiller JS. Update on mammography trends: comparisons of rates in 2000, 2005, and 2008. Cancer, 2011, 117(10): 2209-2218.
20. 杨非, 黄源, 应桂英, 等. 四川省基层医疗卫生服务机构开展宫颈癌和乳腺癌筛查能力的调查. 中国全科医学, 2014, 17(18): 2118-2122.
21. Onega T, Beaber EF, Sprague BL, et al. Breast cancer screening in an era of personalized regimens: a conceptual model and National Cancer Institute initiative for risk-based and preference-based approaches at a population level. Cancer, 2014, 120(19): 2955-2964.
22. 冯雅靖, 方利文, 王卓群, 等. 在中国农村地区妇女人群中整合开展主要慢性病与“两癌”筛查的可行性分析. 中国慢性病预防与控制, 2016, 24(6): 466-469.
23. 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019 版). 中国癌症杂志, 2019, 29(8): 609-680.
24. 中国抗癌协会国家肿瘤临床医学研究中心(天津医科大学肿瘤医院). 中国女性乳腺癌筛查指南. 中国肿瘤临床, 2019, 46(9): 430-432.
25. Zhang J, Sun J, Chen J, et al. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5 931 Chinese women with breast cancer. Breast Cancer Res Treat, 2016, 158(3): 455-462.
26. Lang GT, Shi JX, Hu X, et al. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2 991 patients and 1, 043 controls by next-generation sequencing. Int J Cancer, 2017, 141(1): 129-142.
27. Yao L, Sun J, Zhang J, et al. Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations. Breast Cancer Res Treat, 2016, 156(3): 441-445.
28. Howell A, Anderson AS, Clarke RB, et al. Risk determination and prevention of breast cancer. Breast Cancer Res, 2014, 16(5): 446.
29. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst, 1999, 91(18): 1541-1548.
30. Schonfeld SJ, Pee D, Greenlee RT, et al. Effect of changing breast cancer incidence rates on the calibration of the Gail model. J Clin Oncol, 2010, 28(14): 2411-241.
31. NCCN. NCCN clinical practice guidlines: Breast cancer risk reducetion, version 1.2020. Fort Washington: NCCN, Inc, 2020.
32. Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO Clinical practice guideline update. J Clin Oncol, 2019, 37(33): 3152-3165.
33. 宋丰举, 刘雪鸥, 黄育北, 等. 中国女性良性乳腺疾病的流行现状、危险因素及对乳腺癌筛查效果的影响研究. 成都: 全国肿瘤流行病学和肿瘤病因学学术会议论文集, 2015.
34. Cheng J, Qiu S, Raju U, et al. Benign breast disease heterogeneity: association with histopathology, age, and ethnicity. Breast Cancer Res Treat, 2008, 111(2): 289-296.
35. 新浪网. 中国人口协会发布中国乳腺疾病调查报告. 2010 年 2 月 1 日. http://eladies.sina.com.cn/nx/2010/0201/1059966477.shtml.
36. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med, 2005, 353(3): 229-237.
37. American Cancer Society. Breast cancer facts & figures 2019-2020. Atlanta: American Cancer Society, Inc. 2019.
38. Pankratz VS, Degnim AC, Frank RD, et al. Model for individualized prediction of breast cancer risk after a benign breast biopsy. J Clin Oncol, 2015, 33(8): 923-929.
39. Wang Y, Gao Y, Battsend M, et al. Development of a risk assessment tool for projecting individualized probabilities of developing breast cancer for Chinese women. Tumour Biol, 2014, 35(11): 10861-10869.
40. Dorjgochoo T, Deming SL, Gao YT, et al. History of benign breast disease and risk of breast cancer among women in China: a case-control study. Cancer Causes Control, 2008, 19(8): 819-828.
41. Jacobs TW, Byrne C, Colditz G, et al. Radial scars in benign breast-biopsy specimens and the risk of breast cancer. N Engl J Med, 1999, 340(6): 430-436.
42. 张安秦, 夏建红, 王颀, 等. 广东地区妇女乳腺癌高危因素分析与对策. 南方医科大学学报, 2009, 29(7): 1451-1453.
43. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 2013, 31(23): 2942-296.
44. ACS. Breast cancer prevention and early detection. American Cancer Society, 2020. https://www.cancer.org/content/dam/CRC/PDF/Public/8579.00.pdf.
45. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Practice bulletin No. 164: Diagnosis and management of benign breast disorders. Obstet Gynecol, 2016, 127(6): e141-e156.
46. Cuzick J, DeCensi A, Arun B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol, 2011, 12(5): 496-503.
47. Lavoué V, Fritel X, Antoine M, et al. Clinical practice guidelines from the French College of Gynecologists and Obstetricians (CNGOF): benign breast tumors - short text. Eur J Obstet Gynecol Reprod Biol, 2016, 200: 16-23.
48. Vogel VG. Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction. BMC Med, 2015, 13: 63.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

我国乳腺癌预防若干问题的思考

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content